CyberKnife Radiosurgery of Skull-base Tumors: A UK Center Experience
Open Access
- 27 March 2018
- journal article
- research article
- Published by Cureus, Inc. in Cureus
- Vol. 10 (3) , e2380
Abstract
The study aim was to evaluate patient individualized Cyberknife (R) treatment for heterogeneous skull-base tumors. Patients treated between 2009 and 2013 at The Harley Street Clinic were studied. In total, 66 patients received 15-30 Gy in 1-5 fractions to a median planning target volume (PTV) of 6.4 cc, including patients with secondary, multiple, residual and recurrent tumors, and those with tumors of uncertain pathological type. Outcome analysis was pragmatically restricted to 35 patients who had single, primary tumors treated with curative intent, and sufficient diagnostic and outcome information. Sixteen vestibular schwannoma patients with median PTV 3.8 cc (range 0.81-19.6) received 18-25 Gy in 3-5 fractions: 81% showed no acute toxicity, 50% reported no late toxicity, 71% of symptoms were stable/improved and local control was 100% at 11.4 months median follow-up. Twelve meningioma patients with median PTV of 5.5 cc (range 0.68-22.3) received 17-30 Gy in 1-5 fractions: 83% experienced no acute toxicity, 33% reported no late toxicity, 88% of symptoms were stable/improved and local control was 100% at 22.1 months median follow-up. Seven patients with other tumor types with median PTV of 24.3 cc (range 7.6-100.5) received 15-28.5 Gy in 1-5 fractions: 57% experienced no acute toxicity, 57% reported no late toxicities, 66% of symptoms were stable and local control was 43% at 14.9 months median follow-up. When tumor types were considered together, smaller tumors (PTV < 6.4 cc) showed reduced acute toxicity (p = 0.01). Overall, smaller benign tumors showed low acute toxicity, excellent local control, and good symptom management: a focus on enhanced neurological preservation may refine outcomes. For other tumor types outcome was encouraging: a focus on optimal dose and fractionation scheduling may reduce toxicity and improve local control. Individual patient experiences are detailed where valuable lessons were gained for optimizing local control and minimizing toxicity.Keywords
This publication has 28 references indexed in Scilit:
- Neuro-oncology Virtual Special IssueClinical Oncology, 2016
- Current status of cranial stereotactic radiosurgery in the UKBritish Journal of Radiology, 2016
- Stereotactic radiation treatment of vestibular schwannoma: indications, limitations, and outcomesCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2010
- A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannomaJournal of Neurosurgery, 2010
- MULTISESSION CYBERKNIFE STEREOTACTIC RADIOSURGERY OF LARGE, BENIGN CRANIAL BASE TUMORSNeurosurgery, 2009
- Fractionated Stereotactic Radiotherapy of Glomus Jugulare TumorsStrahlentherapie und Onkologie, 2007
- Staged Stereotactic Irradiation for Acoustic NeuromaNeurosurgery, 2005
- Dose conformity of gamma knife radiosurgery and risk factors for complicationsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Gamma Knife Radiosurgery of Skull Base MeningiomasActa Neurochirurgica, 2000
- Long-term outcomes after meningioma radiosurgery: physician and patient perspectivesJournal of Neurosurgery, 1999